Pancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Pancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer [Phase 2]
Phase 2 study of temsirolimus in combination with bevacizumab in advanced endometrial, ovarian, liver, carcinoid, and pancreatic neuroendocr…
-
FDA approval · 2018-12-12FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., resulting in regu…
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus [Phase 2]
Phase 2 clinical trial update evaluating everolimus in patients with metastatic pancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2018-06-12Clinical Trial Update: Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor [NA]
This completed clinical trial assesses the efficacy and safety of radiofrequency ablation for pancreatic neuroendocrine tumors and pancreati…
-
FDA approval · 2018-04-12FDA Approved: EVEROLIMUS — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s Original Application for Everolimus, establishing a generic version of the branded drug. The a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-03-09FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for octreotide acetate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2018-01-23Clinical Trial Update: A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) [Phase 2]
Phase 2 trial assessing palbociclib in well/moderately differentiated metastatic pancreatic neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2017-12-27Clinical Trial Update: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of AMG 479 in advanced carcinoid tumors and pancreatic neuroendocrine tumors has completed, with results posted in 2017.
-
FDA approval · 2017-11-16FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
FDA has approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. This entry documents the supple…
-
CLINICAL_TRIALS trial_result · 2017-10-19Clinical Trial Update: A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers [Phase 2]
Phase 2 study of Fosbretabulin in pancreatic or gastrointestinal neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-08-29Clinical Trial Update: Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Clinical trial registry update indicating completion of NCT01770405 evaluating needle-based confocal laser endomicroscopy (nCLE) for masses …
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors [NA]
Clinical trial update on doxorubicin-loaded beads for unresectable liver metastases from neuroendocrine tumors; the trial was terminated and…
-
CLINICAL_TRIALS research · 2017-08-25Clinical Trial Update: Biomarker Study in Pancreatic Neuroendocrine Tumours
An update on a biomarker study in pancreatic neuroendocrine tumors sponsored by Uppsala University; the current status is not disclosed.
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.
-
CLINICAL_TRIALS withdrawal · 2017-07-19Clinical Trial Update: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of dovitinib lactate for pancreatic neuroendocrine tumors has been withdrawn.
-
CLINICAL_TRIALS research · 2017-06-29Clinical Trial Update: A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor [Phase 2]
Phase 2 clinical trial evaluating two tegafur-based regimens—tegafur with temozolomide alone versus tegafur with temozolomide plus thalidomi…
-
CLINICAL_TRIALS research · 2017-05-31Clinical Trial Update: Everolimus TDM to Predict Long Term Toxicity
A clinical trial evaluates whether therapeutic drug monitoring of everolimus can predict long-term toxicity in cancer patients.
-
CLINICAL_TRIALS trial_result · 2017-04-13Clinical Trial Update: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy plus Endostatin for advanced pancreatic neuroendocrine tumors has completed, according to C…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project [Phase 1]
Phase 1 COLPAN trial evaluating near-infrared technology to assist laparoscopic resection of pancreatic lesions has completed, including pan…
-
CLINICAL_TRIALS trial_result · 2017-02-03Clinical Trial Update: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer [Phase 2]
Phase 2 trial of pharmacokinetically guided everolimus in patients with breast cancer, pancreatic neuroendocrine tumors, or renal cell carci…
-
CLINICAL_TRIALS trial_result · 2016-12-20Clinical Trial Update: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET [Phase 2]
A Phase 2 trial evaluating everolimus alone or in combination with pasireotide LAR for advanced pancreatic neuroendocrine tumors was termina…
-
CLINICAL_TRIALS trial_result · 2016-12-12Clinical Trial Update: Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating temsirolimus in patients with metastatic neuroendocrine tumors has completed, with results posted in 201…
-
CLINICAL_TRIALS research · 2016-12-01Clinical Trial Update: EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study [NA]
An update on a prospective study evaluating endoscopic ultrasound-guided ethanol-lipiodol ablation for pancreatic neuroendocrine tumors to a…
-
CLINICAL_TRIALS trial_result · 2016-10-19Clinical Trial Update: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]
A Phase 1 trial assessing the combination of pasireotide and RAD001 (everolimus) in patients with advanced neuroendocrine tumors has complet…
-
FDA approval · 2016-10-12FDA Approved: ZORTRESS — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for ZORTRESS (everolimus) submitted by Novartis Pharmaceuticals Corporation. The action likely a…